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compared to HAQ-DI (0.004 improvement in utility per unit decrease in PASI). Using 
these algorithms, the incremental cost-effectiveness ratios (ICER) were calculated 
for each biologic versus standard of care. For each biologic ICERs coefficient of vari-
ation (standard deviation/mean) was approx. 17%. ConClusions: HAQ-DI is the 
key influencing variable in deriving utility values for PsA patients in the current 
algorithms. In biologic cost-effectiveness models, ICER is sensitive to the algorithms 
used. The analysis suggests that there may be a need of an improved algorithm to 
inform cost-effectiveness models for predicting utility more accurately. This may 
help the healthcare decision makers to make more informed decisions.
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The ASSociATion beTween DiSeASe AcTiviTy AnD QuAliTy of life 
AMong PATienTS wiTh AnkyloSing SPonDyliTiS in PoliSh PoPulATion
Malinowski K, Kawalec P
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objeCtives: The aim of this study was to assess the disease activity and quality of 
life of patients with ankylosing spondylitis (AS) in Polish population. Methods: 
On-line questionnaire survey was performed to obtain data on disease activity 
and the quality of life. We used Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and EQ-5D questionnaires with visual analogue scale (VAS). BASDAI score 
was obtained using on-line calculator. EQ-5D states were converted into utilities for 
European population. The Spearman’s correlation was used to present the associa-
tion between the disease activity and the quality of life. Results: A total number of 
66 questionnaires was obtained. Patients reported mostly the problems with general 
discomfort and morning stiffness represented by 8 points on BASDAI scale, followed 
by tiredness and neck pain represented by 7 points and other pain represented by 5 
points. Almost 30% of patients reported that morning stiffness lasts longer than two 
hours. The mean BASDAI score was 5.87 (SD: 1.81). Of all patients, 68% reported some 
(highest reported state) problems with mobility, 47% with looking after himself. A lot 
(highest reported state) of problems with usual activities reported 4% of patients, a 
lot of pain and discomfort was reported by 13% of patients and with feeling worried 
by 6%. In all domains “some problems” was the most frequent answer resulting that 
the most common EQ-5D state was “22222”. The mean utility was 0.52 (SD: 0.195) 
varied from 0 to 1. Patient reported visual analogue scale was 47 (SD: 26) varied 
from 0 to 100. BASDAI score was significantly correlated with utility (-0.635) and VAS 
(-0.620). ConClusions: Ankylosing spondylitis significantly reduces the quality of 
life. The higher the BASDAI score representing the higher disease activity and the 
lower the quality of life, reported as both EQ-5D utility and VAS.
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non-rADiogrAPhic AxiAl SPonDyloArThriTiS TreATMenT:  
A croSS-SecTionAl euroPeAn STuDy in The reAl worlD SeTTing
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objeCtives: Non-radiographic axial spondyloarthritis (nr-axSpA) is an inflammatory 
arthritic disease characterized by sacroiliac joint inflammation. Studies indicate that 
nr-axSpA is a long-term chronic condition and can impose a considerable burden on 
the patients’ physical function, impairment, and health-related quality of life. This 
analysis aimed to investigate whether elements of the burden associated with nr-
axSpA are avoidable. Methods: Data were from the 2014 nr-axSpA Disease Specific 
Programme, a cross-sectional, multi-national survey of patients and rheumatolo-
gists conducted in France, Germany, Italy, Spain and the UK. Rheumatologists com-
pleted forms containing patient demographics, clinical results and symptomology. 
Patients completed patient self-completions (PSCs) containing the Work Productivity 
and Activity Impairment questionnaire and EuroQoL-5D (EQ-5D-3L) with the visual 
analogue scale (EQ-VAS). Biologic treatment naïve patients considered eligible for bio-
logics by the physician were compared to patients receiving biologics for ≥ 6 months. 
Observations were weighted to ensure findings were more representative of the 
patient population. The weight was applied to all percentages, means and standard 
deviations (SDs). Appropriate weighted univariate regressions were performed to 
test for significance. Results: The analysis comprised of 310 patients (mean age 
42.5±11.8 [SD], 74.8% male), with 123 biologic-naïve and 187 biologic-treated patients. 
Only 76 PSCs were completed in total. Compared to biologic-treated patients, biologic-
naïve patients had greater overall work impairment (37.1% vs. 18.8%), presentee-
ism (27.6% vs. 15.8%) and activity impairment (31.4% vs. 22.5%). Additionally, more 
biologic-naïve patients were currently experiencing acute episodes (12.7% vs. 2.5%) 
and inflammatory back pain (69.5% vs. 38.5%) (all p< 0.05). There were no observed 
differences between cohorts regarding mean EQ-5D utility score (0.81 vs. 0.82) or 
EQ-VAS (65.5 vs. 64.8). ConClusions: A potential unmet has been highlighted in 
nr-axSpA patient management, which could be due to restrictions upon physicians 
prescribing choices. Reducing the duration between diagnosis and biologic treatment 
prescription could potentially lessen the societal and clinical burden of nr-axSpA.
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objeCtives: To describe residual skin and joint disease and health-related qual-
ity of life (HRQoL) in psoriatic arthritis (PsA) patients treated with biologics, and 
explore the impact of residual disease on HRQoL, work productivity, and switching 
therapies. Methods: This was a retrospective analysis of 2013/14 US-EU5 Adelphi 
Real World cross-sectional survey data from dermatologists, rheumatologists, and 
PsA patients receiving biologics for ≥ 6-months. Outcomes included: EuroQol-5 
Dimension (EQ-5D), Health Assessment Questionnaire Disability Index (HAQ-DI) 
(rheumatologists), PROMIS-HAQ) (dermatologists), Dermatology Life Quality Index 
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PATienT-rePorTeD ouTcoMeS in STuDieS PubliSheD in 2014: which ToolS 
hAve been MoST coMMonly uSeD in STuDieS of MuSculoSkeleTAl 
DiSorDerS?
Martin A
Crystallise Ltd., London, UK
objeCtives: To determine which patient-reported outcome (PRO) tools were 
used in studies on musculoskeletal diseases published in 2014. Methods: An 
evidence surveillance process was established based on a systematic search 
of PubMed, incorporating all studies published from 2010 and updated weekly, 
with a final search on 18 May 2015. Abstracts identified by the search that 
reported quality of life outcomes in musculoskeletal disorders were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified from the 
abstract alone, where possible. Results: The search identified 1,980 articles 
published in 2014. Of these, 197 (10%) were in musculoskeletal disorders. The 
most commonly researched diseases were osteoarthritis (19 articles), rheu-
matoid arthritis and back pain (14 each), fibromyalgia and fractures (10 each), 
and ankylosing spondylitis (9). Overall, 160 different PRO or clinician-reported 
instruments were cited in the 197 abstracts, with 93 articles citing more than 
one tool. Pain instruments were most commonly used (82 articles included 
either VAS or unspecified pain measurement). Utility measurement was made 
in 36 studies, with SF-36 used twice as often as either SF-12 or EQ-5D. PROs most 
commonly cited included WOMAC (13 articles), DASH (9), KOOS (9), HAQ (8), 
WHOQOL-BREF (6), FIQ and WOSI (5 each). The PRO used was not specified in 52 
article abstracts: 22 of the 143 primary research articles, 7 of 18 study protocols 
and 30 of 34 systematic reviews. ConClusions: A wide range of musculoskel-
etal disorders were researched in 2014, with little overlap in PRO tools used 
even within diseases. Standardisation of tool use would aid comparison of out-
comes across studies. Evidence surveillance including study protocols, results 
and systematic reviews may help identify trends in PRO use within specific 
diseases.
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Pro clAiMS in fibroMyAlgiA: A review of The lAbelS of ProDucTS 
APProveD by The fDA AnD The eMA
Acquadro C1, Perret C1, Regnault A2
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objeCtives: Fibromyalgia is a chronic pain syndrome characterized by increased 
sensitivity to pain, fatigue, muscle stiffness, difficulty sleeping, problems with 
mental processes (known as “fibro-fog”), such as problems with memory and con-
centration, headaches, and irritable bowel syndrome. The objectives of this study 
were 1) to identify patient-reported outcome (PRO) claims in products specifically 
approved for the treatment of fibromyalgia by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) since 1995, and 2) to identify 
the endpoint positioning of the PROs when measured. Methods: The websites 
of the FDA and the EMA were explored to identify all products approved specifi-
cally for fibromyalgia. PROLabels was used to identify products with a PRO claim 
in label. All corresponding clinical reviews (FDA), and assessments reports (EMA) 
were reviewed to check for endpoint positioning. Results: Since 1995, only three 
products have been approved with the specific indication of fibromyalgia (three by 
the FDA, i.e., duloxetine, milnacipran and pregabalin). None have been approved by 
the EMA. All of the products approved by the FDA include PRO claims in their label: 
reduction in pain, improvements in function, and in patient global impression of 
change (PGIC). When the medical review was available (duloxetine, milnacipran), 
the analysis of endpoint positioning showed that reduction in pain (either meas-
ured by the overall score of the Brief Pain Inventory or a Visual Analog Scale) was 
the primary efficacy endpoint. In one case (duloxetine), and for one study, the PGIC 
was also considered as a primary endpoint. Function was a secondary endpoint 
measured either by the Fibromyalgia Impact Questionnaire (duloxetine, pregaba-
lin) or the SF-36 Physical Component Summary (milnacipran). ConClusions: 
PROs are essential to the evaluation of fibromyalgia products and are included in 
the labels of all products approved by the FDA. Reduction in pain is the key primary 
endpoint.
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unDerSTAnDing The relATionShiP beTween heAlTh ASSeSSMenT 
QueSTionnAire-DiSAbiliTy inDex (hAQ-Di), PSoriASiS AreA SeveriTy 
inDex (PASi), AnD QuAliTy of life (Qol) AnD iTS influence on  
coST-effecTiveneSS in PSoriATic ArThriTiS (PSA)
Gunda P1, Syeda SS1, Jugl SM2
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG, Basel, 
Switzerland
objeCtives: To evaluate the relationship between the disease activity measures 
(HAQ, PASI) and patient’s QoL based on different utility mappings and its influ-
ence on cost-effectiveness (CE) Methods: The identified algorithms of a litera-
ture research project that includes database screening of publications in English 
language from 1996-2015 have been extracted and the differences have been 
explored in a CE model for PsA. The model follows a decision tree for the first 12 
weeks and Markov structure for rest of the time horizon with three month cycle 
length. Results: The research retrieved 13 different algorithms to derive utilities in 
PsA patients based on clinical study data. In these studies, utilities were measured 
either with the SF-36 (n= 5) or the EQ-5D (n= 9) instruments. Different algorithms 
used different independent variables such as HAQ-DI, PASI or Disease Activity Score 
28 (DAS28) to predict utility values. The arthritis component of the disease was 
measured either through HAQ-DI (n= 11) or DAS28 (n= 2), whereas PASI was used 
for the skin component (n= 4). Most of the algorithms were using a linear approach 
(n= 11). Among these linear algorithms one unit decrease of HAQ-DI improves 
patient’s utility by 0.1 to 0.3 units. Effect of PASI on utility was much smaller as 
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objeCtives: To evaluate the association between improvements in clinical 
and patient-reported outcomes (PROs) and improvements in workplace and 
household productivity in axial spondyloarthritis (axSpA) patients treated with 
certolizumab pegol (CZP), including ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). Methods: Analyses used Week (Wk) 24 data from 
the double-blind, placebo-controlled period of RAPID-axSpA (NCT01087762), for 
patients originally randomized to CZP. Responders and non-responders for clini-
cal outcomes and PROs were compared in terms of change from baseline (CFB) 
in workplace and household productivity, assessed with the arthritis-specific 
Work Productivity Survey (WPS). Groups were compared using a non-parametric 
bootstrap-t method. LOCF was used for ASDAS and WPS outcomes; NRI for ASAS40 
and PRO MCIDs. Results: 218 CZP patients entering RAPID-axSpA were ana-
lyzed at Wk24 (121 AS; 97 nr-axSpA). Patients employed at Wk24: 73.9% axSpA; 
73.6% AS; 74.2% nr-axSpA. Greater improvements in workplace productivity were 
reported by CZP-treated axSpA patients who achieved a clinical response (pres-
enteeism CFB [responders/non-responders]: -3.9/-1.0 for ASAS40; -4.3/-0.7 for 
ASDAS-MI) and reported improved physical function and less back pain (pres-
enteeism CFB [responders/non-responders]: -3.9/0.7 for BASFI MCID; -3.5/1.3 for 
total back pain MCID). Clinical responses and symptom relief were also associated 
with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -4.8/-3.6 for ASAS40; -5.1/-2.2 for BASFI 
MCID; -5.6/-0.6 for ASQoL MCID) and greater social participation (CFB in family/
social/leisure days missed [responders/non-responders]: -3.3/-1.8 for ASDAS-MI; 
-2.9/-0.8 for total back pain MCID). Nr-axSpA responders reported numerically 
greater improvements in productivity than AS responders (presenteeism CFB for 
ASDAS-MI [responders/non-responders]: -5.5/-0.5 in nr-axSpA; -3.4/-0.9 in AS). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productiv-
ity differences. ConClusions: Achievement of clinical responses and symptom 
relief were associated with increased workplace and household productivity in 
CZP-treated axSpA patients, including AS and nr-axSpA.
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elDerly oSTeoPoroSiS SuSPecTS wiThouT DiAgnoSiS – inTeriM DATA 
froM A gerMAn geriATric PrAcTice
Schmid T1, Brumme UM1, Kemerle S2, Zimmer K2
1Amgen GmbH, Munich, Germany, 2Leipziger Gesundheitsnetz e.V., Leipzig, Germany
objeCtives: Elderly patients are at higher risk for osteoporotic (OP) fractures com-
pared with the general population[1], with low-trauma fractures in elderly patients 
associated with increased mortality risk.[2] In a high proportion of patients with 
an OP fracture, OP is previously undiagnosed and no OP-medication initiated[3]. 
This market-research aimed to assess the OP-risk in geriatric patients without 
OP-diagnosis. [1] Cooper C et al. (1992): Hip fractures in the elderly: a world-wide pro-
jection. Osteoporosis international; 2(6):285-289. [2] Bliuc et al.: Mortality risk associ-
ated with low-trauma osteoporotic fracture and subsequent fracture in men and 
women. JAMA 2009 Feb 4; 301(5):513-21. [3] Klein S et al.: Osteoporose in Deutschland 
– Epidemiologie und Versorgung, 56. GMDS Jahrestagung (2011) Methods: New 
patients to a German geriatric-practice without OP-diagnosis, completing a ques-
tionnaire (QU) with their physician evaluating OP-risk factors determined by the 
German-S3-OP-guideline[1], e.g. age, gender, BMI, were eligible. A total of 29 ques-
tions were assigned 1 or 2 points depending on OP-risk impact (total points: 0 - 31). 
A score ≥ 3 identified “OP-suspects” who were to be referred to an orthopedist. 
In orthopedic-confirmed OP-cases, OP-medication was initiated. We present 
interim data (patients completing the QU from 10/14 to 3/15). [1] http://www.dv-
osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20
Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf Results: Among 
53 patients included in the interim analysis, mean age was 78 years and 40 (76%) 
were post-menopausal women; 23 (43%) had co-existing diabetes and 15 (28%) 
chronic-renal-insufficiency. One-third (17 [32%]) had experienced ≥ 1 fracture after 
the age of 50. All 53 patients were identified as “OP-suspects” (mean QU-score, 
6.6 points); 29 (55%) scored ≥ 7 points indicating very high OP-risk. To date, 26 
patients had returned to the geriatric practice, with 12 (46%) having an orthopedics-
confirmed OP-diagnosis. ConClusions: Our data suggest proactive evaluation 
and identification of OP is needed in the elderly population, to improve disease 
management including initiation of therapy as appropriate.
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objeCtives: Osteoporosis is a chronic progressive disease characterized by low bone 
mass and deterioration of bone structure, leading to an increate risk of fractures.The 
aim of this study was to investigate the determinants of non-persistence and impact 
of persistence on the risk of fractures. Methods: The data used for this study were 
(DLQI), and Work Productivity and Activity Impairment Index (WPAI). Patients were 
classified as achieving: full, partial, or no benefit from treatment. Full benefit was no 
PsA flare, psoriasis body surface area (BSA) = 0; a “mild” rating of physician/patient 
global perception of PsA and all skin and joint symptoms. No benefit was a PsA flare 
or physician/patient global perception of PsA that remained “moderate/severe” or 
worsened since initiation of current therapy. Everyone else achieved partial benefit. 
HRQoL was described for those with partial benefit. Residual disease was defined 
as BSA > 0%, ≥ 1 tender or swollen joint, or ≥ 1 skin or joint symptom rated as 
“moderate/severe”. Adjusted associations were estimated between residual disease, 
HRQoL, productivity and switching. Results: The sample included 398 patients; 
19.6% achieved full, 49.0% partial, and 31.4% no benefit. Of those achieving partial 
benefit, 43.1% were female, mean (SD) age 50.1 (11.8), PsA duration in months 97.9 
(91.0), BSA 8.0% (10.2%). Mean (SD) HRQoL scores for partial benefit patients were: 
0.81 (0.20) EQ-5D; 27.01, (27.10) overall work impairment; 5.17 (5.16) DLQI; 11.03 
(12.33) PROMIS HAQ; 0.35 (0.41) HAQ-DI. Residual disease was not associated with 
switching. Residual skin disease was not associated with lower EQ5D or higher 
WPAI scores. ConClusions: A substantial proportion of patients yield partial or 
full benefit from biologics. In this sample, residual skin disease did not impact 
HRQoL or work productivity.
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eSTiMATing The MoneTAry vAlue of relief of TenniS elbow: A 
conTingenT vAluATion STuDy of willingneSS-To-PAy
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objeCtives: To estimate the willingness-to-pay (WTP) for symptom relief of tennis 
elbow and examine whether WTP is related to injury characteristics, clinical out-
comes, or other socio-demographic factors. Methods: This cross-sectional WTP, 
contingent valuation study was performed alongside a randomised controlled trial 
comparing the addition of physiotherapy to corticosteroid injection in 165 par-
ticipants with tennis elbow. The contingent value scenario constructed required 
participants to decide the monetary value (AUD) they would pay for a quick and 
non-invasive new treatment for relief of their elbow condition. Participants were 
told to consider that their symptoms would persist for the next 12 months if left 
untreated. The efficacy of this new treatment was defined as complete recovery in 
50% of people treated. Two WTP approaches (bidding game and binary response) 
were administrated in blocks of 15 consecutive participants. For both methods, 
participants were randomly allocated a starting bid from values of $50, $650, $1250 
or $1850. Results: The bidding game approach was performed in 73 participants. 
WTP values ranged from $50 – 10000 [median WTP (IQR): $695 ($390, $940)]. WTP was 
significantly associated with an individual’s gross income, greater pain and disabil-
ity and a worsening condition. The binary response approach was performed in 87 
participants. All participants accepted a $50 bid, while more than half accepted $650 
and $1250 bids. Using this approach, participants were more likely to accept higher 
values if they had experienced greater pain and disability, a worsening condition and 
reduced pain-free grip of their affected arm. ConClusions: This study examined 
the economic value that participants with tennis elbow ascribe to relief of their 
condition. The relationship between this monetary value and an individual’s injury 
characteristics and income was also demonstrated. In future work, we propose 
to compare these WTP estimates with indicators of health-related quality-of-life, 
which were also collected during this study.
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objeCtives: To evaluate the association between improvements in clinical and 
patient-reported outcomes (PROs) and improvements in workplace and household 
productivity in psoriatic arthritis (PsA) patients treated with certolizumab pegol 
(CZP). Methods: Analyses used Week (Wk) 24 data from the double-blind, placebo-
controlled period of RAPID-PsA (NCT01087788), for patients originally randomized to 
CZP. Responders and non-responders for clinical outcomes and PROs were compared 
in terms of change from baseline (CFB) in workplace and household productivity, 
assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were 
compared using a non-parametric bootstrap-t method. LOCF was used for WPS out-
comes; NRI for clinical outcomes and PRO MCIDs. Results: 273 CZP patients entering 
RAPID-PsA were analyzed at Wk24. 61.9% of patients were employed at Wk24. Greater 
improvements in workplace productivity were reported by CZP-treated patients who 
achieved improved joint and skin outcomes, as well as disease remission (absentee-
ism CFB [responders/non-responders]: -1.4/-0.5 for ACR20; -1.9/-0.4 for PASI75; -1.5/-
0.6 for DAS28 remission). Clinically meaningful reductions in disability, pain and 
fatigue were also associated with increased workplace productivity (presenteeism 
CFB [responders/non-responders]: -5.4/-0.9 for HAQ-DI MCID; -3.4/-2.6 for pain MCID; 
-4.4/-0.9 for fatigue MCID). Clinical responses and symptom relief were also associ-
ated with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -5.8/-1.0 for ACR20; -5.5/-0.9 for PASI75; -5.1/-
3.0 for DAS28 remission; -6.0/-1.9 for HAQ-DI MCID; -5.1/-1.3 for pain MCID; -5.1/-1.7 
for fatigue MCID) and greater social participation (CFB in family/social/leisure days 
missed [responders/non-responders]: -3.0/-1.5 for PsARC; -2.9/-2.3 for fatigue MCID). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productivity 
differences. ConClusions: Achievement of disease remission, clinically meaningful 
improvements in joint and skin outcomes and symptom relief were associated with 
increased workplace and household productivity in PsA patients treated with CZP.
